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Abstract: 
This observational study was conducted upon a sample of 108 chronic HCV patients (chosen via non-probability – 
consecutive sampling) presenting to the Dept. of Medicine - Abbasi Shaheed Hospital, Karachi from February 5, 2018 
to August 31, 2018. As per the standard protocol, a dose of pegylated interferon-α2a was administered at week 1 and 
then weekly with daily oral ribavirin for 24 or 48 weeks. Genotyping and quantification of hepatitis C virus (HCV) 
RNA were done using molecular methods. Clinical and serological (viral load) data obtained was analyzed using 
SPSS version 21.0 and MS. Excel 2013. Out of 108 participants 71 were males and 37 were females, with a mean age 
of 38 years for males and 23 years for females. A total of 53 patients were infected with HCV genotype 1, 47 with 
genotype 2 and 8 with both genotypes 1 and 2. At the end of follow-up, 87 patients attained sustained virological 
response (SVR). After accounting for confounders, body mass index (BMI) and genotype were related to viral load 
decline at day 2, baseline viral load and high-density lipoprotein (HDL) cholesterol levels were correlated with viral 
load decline between days 2 and 28. Genotype, baseline viral load and BMI independently predicted rapid virological 
response. After careful consideration of the results, it can be concluded that HCV genotype, baseline viral load, pre-
treatment BMI and HDL have a significant effect on early viral load decline of chronic HCV patients with interferon-
based therapy.  
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INTRODUCTION: 
Hepatitis C virus (HCV) infection is the major cause 
of chronic liver disease and hepatocellular carcinoma 
worldwide. [1] The goal of treating chronic HCV 
patients is to eradicate the virus or, in a clinical term, 
to attain a sustained virological response (SVR; 
defined as undetectable serum HCV RNA level at 24 
weeks after treatment cessation). [2]  
However, currently approved pegylated interferon 
(PEG-IFN) plus ribavirin (RBV) therapy has many 
unpleasant side effects and is only effective in a certain 
proportion of HCV patients. [3] Therefore, identifying 
baseline and on-treatment factors predictive of SVR in 
HCV patients is important in terms of increasing 
efficacy, avoiding unnecessary side effects and saving 
medical costs.  
Several factors have been linked to the therapeutic 
response of HCV patients, including viral factors, [4] 
host factors, [5] metabolic factors, [6] histological 
factors, [7] the regimen used [8] and the duration of 
infection. [9] Among these factors, early viral kinetics 
following therapy has become increasingly recognized 
and is widely used in both clinical trials and daily 
practice. [10]  
Considering the clinical significance of early viral 
kinetics, it is thus reasonable to investigate the 
association of other predictors with viral load decline. 
These attempts not only provide information on 
individualized treatment, but also elucidate the 
underlying mechanisms of these predictors. Although 
patients in our part of the world (south-east Asia) are 
more likely to achieve an SVR to combination therapy 
than Caucasians with HCV, [11] the influence of 
various host and viral factors on early viral load 
decline in our part of the world among HCV patients 
deserves further study. [12]  
Thus, this study recruited treatment naive patients with 
HCV and administered a combination therapy of PEG-
IFN-a2a plus RBV, in an attempt to generate much 
needed evidence in this regard (the effect of various 
host, viral and metabolic factors on early viral load 
decline). The results shall prove helpful in providing a 
basis for future interventional research. 
METHODOLOGY: 
This observational study was conducted upon a sample 
of 108 chronic HCV patients (chosen via non-
probability – consecutive sampling) presenting to the 
Dept. of Medicine - Abbasi Shaheed Hospital, Karachi 
from February 5, 2018 to August 31, 2018. Chronic 
HCV infection was defined as the positivity of both 
anti-HCV antibodies and serum HCV RNA for >6 
months. As per the standard protocol, a dose of 
pegylated interferon-α2a was administered at week 1 
and then weekly with daily oral ribavirin for 24 or 48 
weeks. Genotyping and quantification of hepatitis C 
virus (HCV) RNA were done using molecular 
methods. Clinical and serological (viral load) data 
obtained was analyzed using SPSS version 21.0 and 
MS. Excel 2013. 
 
Inclusion Criteria:  
Consenting patients (of both genders and all ages) 
presenting with chronic HCV (defined as the positivity 
of both anti-HCV antibodies and serum HCV RNA for 
>6 months and had serum alanine aminotransferase 
(ALT) levels ≥2× the upper limit of normal on two 
occasions within the past 6 months) were included in 
the study.  
 
Exclusion criteria:  
Non-consenting patients and patients who had 
received prior interferon, other experimental antiviral 
or immunosuppressive therapy were excluded from 
the sample. Also excluded were, patients positive for 
hepatitis B surface antigens or HIV antibodies, 
patients with a history or serological evidence of 
autoimmune liver disease, inheritable disorders (such 
as haemochromatosis or Wilson’s disease), renal 
insufficiency, a history of excess alcohol intake (daily 
alcohol consumption >20 g) or active drug abuse. 
 
RESULTS: 
Out of 108 participants 71 were males and 37 were 
females, with a mean age of 51 years for males and 45 
years for females.  
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A total of 53 patients were infected with HCV genotype 1, 47 with genotype 2 and 8 with both genotypes 1 and 2. 
 
At the end of follow-up, 87 patients attained sustained 
virological response (SVR). After accounting for 
confounders, body mass index (BMI) and genotype 
were related to viral load decline at day 2, baseline 
viral load and high-density lipoprotein (HDL) 
cholesterol levels were correlated with viral load 
decline between days 2 and 28. Genotype, baseline 
viral load and BMI independently predicted rapid 
virological response. 
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Characteristic 2-tailed sig  
B.M.I (kg/m2) P = 0.05 
Genotype 2 P < 0.01 
HDL (mg/dl) P = 0.08 
HCV RNA, log10 (IU/ml) P < 0.01 
 
DISCUSSION: 
Studies on early viral kinetics during treatment of 
chronic HCV infection have greatly improved our 
understanding about the pathophysiology of HCV 
infection and thus, harbored several clinical 
implications. For example, knowing the influence of 
various factors on HCV dynamics could help 
individualize antiviral treatment. [13] 
In this study, we found that genotype, baseline viral 
load, BMI and pretreatment HDL were independently 
associated with early viral load decline and that 
genotype, baseline viral load and the viral load decline 
at day 28 were independent predictors of SVR. These 
data could optimize current standard of care and 
elucidate the underlying mechanisms of these 
predictors. [14] 
A previous pilot study from Taiwan demonstrated a 
better virological response rate than the Western report 
(genotype 1 patients received 6 months of PEG-IFN-
α2b plus RBV had an SVR up to 65.8%). [15] In 
addition, data to support shorter treatment duration for 
genotype 2 patients were also noted.  
On the basis of these observations, the Bureau of 
National Health Insurance in Taiwan allows the 
reimbursement of 24-week rather than 48-week 
interferon-based treatment for HCV genotype 1 
patients. This is the reason why only most of our 
genotype 1 patients received a 48-week treatment and 
fewer of them received a 24-week treatment. [16] 
The use of viral load decline is inherently limited by 
the value of PCR negativity, and thus the decline 
cannot be greater than the difference between the 
baseline viral load and the value of PCR negativity. 
However, the viral load decline could render the 
information other than HCV RNA negativity in 
monitoring on-treatment virological response. 
Therefore, the combination of these qualitative and 
quantitative data will be more informative to 
practicing physicians. [17] 
The duration of HCV infection, a known predictor of 
the therapeutic efficacy, was not included in our 
analyses because of possible recall bias. These data 
will certainly help clinicians optimize current therapy 
for HCV and elucidate the underlying mechanisms of 
these predictors. 
 
CONCLUSION: 
After careful consideration of the results, it can be 
concluded that HCV genotype, baseline viral load, 
pre-treatment BMI and HDL have a significant effect 
on early viral load decline of chronic HCV patients 
with interferon-based therapy. 
 
REFERENCES: 
1. Wedemeyer H, Dore GJ, Ward JW. Estimates on 
HCV disease burden worldwide–filling the gaps. 
Journal of viral hepatitis. 2015 Jan;22:1-5. 
2. Innes HA, McDonald SA, Dillon JF, Allen S, 
Hayes PC, Goldberg D, Mills PR, Barclay ST, 
Wilks D, Valerio H, Fox R. Toward a more 
complete understanding of the association 
between a hepatitis C sustained viral response and 
cause‐specific outcomes. Hepatology. 2015 
Aug;62(2):355-64. 
3. Younossi ZM, Stepanova M, Nader F, Henry L. 
Patient‐reported outcomes of elderly adults with 
chronic hepatitis C treated with interferon‐and 
ribavirin‐free regimens. Journal of the American 
Geriatrics Society. 2016 Feb;64(2):386-93. 
4. Wen SC, Cheng LC, Hsu JH, Lai HW, Shih PC, 
Tsai CC, Kuo WH. Assessment of baseline 
pretreatment factors and on‐treatment virological 
response to predict sustained virological response 
in patients with chronic hepatitis C treated with 
IAJPS 2019, 06 (03), 5309-5313                      Shaista Ahmed et al                    ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 5313 
pegylated interferon and ribavirin. Advances in 
Digestive Medicine. 2017 Mar;4(1):4-11. 
5. Sreejith Vasudevan S, Kavimandan A, Kalra N, 
Nayak B, Thakur B, Das P, Gupta SD, Panda SK, 
Acharya SK. Demographic profile, host, disease 
& viral predictive factors of response in patients 
with chronic hepatitis C virus infection at a 
tertiary care hospital in north India. The Indian 
journal of medical research. 2016 
Mar;143(3):331. 
6. Rehermann B. HCV in 2015: Advances in 
hepatitis C research and treatment. Nature 
Reviews Gastroenterology & Hepatology. 2016 
Jan 21;13(2):70. 
7. Akhtar E, Manne V, Saab S. Cirrhosis regression 
in hepatitis C patients with sustained virological 
response after antiviral therapy: a meta‐analysis. 
Liver International. 2015 Jan;35(1):30-6. 
8. Kohli A, Osinusi A, Sims Z, Nelson A, Meissner 
EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb 
C, Gross C. Virological response after 6 week 
triple-drug regimens for hepatitis C: a proof-of-
concept phase 2A cohort study. The Lancet. 2015 
Mar 21;385(9973):1107-13. 
9. Simmons B, Saleem J, Heath K, Cooke GS, Hill 
A. Long-term treatment outcomes of patients 
infected with hepatitis C virus: a systematic 
review and meta-analysis of the survival benefit 
of achieving a sustained virological response. 
Clinical Infectious Diseases. 2015 May 
17;61(5):730-40. 
10. Fourati S, Guedj J, Chevaliez S, Nguyen TH, 
Roudot‐Thoraval F, Ruiz I, Soulier A, Scoazec G, 
Varaut A, Poiteau L, Francois M. Viral kinetics 
analysis and virological characterization of 
treatment failures in patients with chronic 
hepatitis C treated with sofosbuvir and an NS 5A 
inhibitor. Alimentary pharmacology & 
therapeutics. 2018 Mar;47(5):665-73. 
11. Vutien P, Hoang J, Brooks Jr L, Nguyen NH, 
Nguyen MH. Racial disparities in treatment rates 
for chronic hepatitis C: analysis of a population-
based cohort of 73,665 patients in the United 
States. Medicine. 2016 May;95(22):212-218. 
12. Raja R, Baral S, Dixit NM. Interferon at the 
cellular, individual, and population level in 
hepatitis C virus infection: Its role in the 
interferon‐free treatment era. Immunological 
reviews. 2018 Sep;285(1):55-71. 
13. Ferenci P. Predictors of response to therapy for 
chronic hepatitis C. InSeminars in liver disease 
2004 May (Vol. 24, No. S 2, pp. 25-31). 
Copyright© 2004 by Thieme Medical Publishers, 
Inc., 333 Seventh Avenue, New York, NY 10001, 
USA.. 
14. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. 
Predicting response in hepatitis C virus therapy. 
Alimentary pharmacology & therapeutics. 2006 
Apr;23(8):1043-54. 
15. Davis GL, Wong JB, McHutchison JG, Manns 
MP, Harvey J, Albrecht J. Early virologic 
response to treatment with peginterferon alfa‐2b 
plus ribavirin in patients with chronic hepatitis C. 
Hepatology. 2003 Sep;38(3):645-52. 
16. Poynard T, Marcellin P, Lee SS, Niederau C, 
Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem 
S, Trepo C, Albrecht J. Randomised trial of 
interferon α2b plus ribavirin for 48 weeks or for 
24 weeks versus interferon α2b plus placebo for 
48 weeks for treatment of chronic infection with 
hepatitis C virus. The Lancet. 1998 Oct 
31;352(9138):1426-32. 
17. Alonso R, Pèc F, López-Roa P, Alcalá L, Rodeño 
P, Bouza E. HCV core-antigen assay as an 
alternative to HCV RNA quantification: A 
correlation study for the assessment of HCV 
viremia. Enfermedades infecciosas y 
microbiologia clinica (English ed.). 2018 Mar 
31;36(3):175-8. 
